Evidence map›Paper›PMID 40488901›Full record

ArticleJournal of neurology2025

Neuropathological examination of 12 cases of familial Parkinson's disease with LRRK2 I2020T mutation including tau and TDP-43 pathology.

Akiko Uchino, Kazuko Hasegawa, Saburo Yagishita, Makiko Nagai, Mieko Ogino, Yutaka Ogino, Hiroyuki Hatsuta, Shigeo Murayama, Yuko Saito

Abstract read
In one paragraph

Article in Journal of neurology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Review
  2. Review
  3. LRRK2 as a Potential Disease-Modifying Target in Sporadic Parkinson's Disease.Movement disorders : official journal of the Movement Disorder Society · 2026
    Review
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Akiko UchinoDepartment of Neuropathology (Brain Bank for Aging Research), Tokyo Metropolitan Geriatric Hospital and Institute of Gerontology, Itabashi-ku, Tokyo, Japan.
Kazuko HasegawaDepartment of Neurology, National Hospital Organization Sagamihara National Hospital, Sagamihara-shi, Kanagawa, Japan.
Saburo YagishitaDepartment of Neurology, National Hospital Organization Sagamihara National Hospital, Sagamihara-shi, Kanagawa, Japan.
Makiko NagaiDepartment of Neurology, Kitasato University School of Medicine, Sagamihara-shi, Kanagawa, Japan.
Mieko OginoDepartment of Neurology, Kitasato University School of Medicine, Sagamihara-shi, Kanagawa, Japan.
Yutaka OginoDepartment of Neurology, Kitasato University School of Medicine, Sagamihara-shi, Kanagawa, Japan.
Hiroyuki HatsutaDepartment of Neuropathology (Brain Bank for Aging Research), Tokyo Metropolitan Geriatric Hospital and Institute of Gerontology, Itabashi-ku, Tokyo, Japan.
Shigeo MurayamaDepartment of Neuropathology (Brain Bank for Aging Research), Tokyo Metropolitan Geriatric Hospital and Institute of Gerontology, Itabashi-ku, Tokyo, Japan.
Yuko SaitoDepartment of Neuropathology (Brain Bank for Aging Research), Tokyo Metropolitan Geriatric Hospital and Institute of Gerontology, Itabashi-ku, Tokyo, Japan. yukosabbar@gmail.com.

Funding

AMED JPMH23FC1008JSPS KAKENHI Grant-In-Aid for Scientific Research (C) 22K07550MEXT/JSPS KAKENHI JP22H04923
6 · The paper itself

Abstract

We previously reported a clinicopathological examination in the Sagamihara family, familial PD with LRRK I2020T mutation, highlighting the most common neuropathological finding as pure nigral degeneration without Lewy bodies (LBs). We applied immunohistochemical analysis to seven previously reported cases and evaluated five additional cases for a full neuropathological examination (altogether 12 cases). All cases exhibited nigral degeneration with a relatively preserved locus coeruleus (LC). Synuclein pathology was found in four cases, one of which showed multiple system atrophy pathology, and three showed LB pathology. Tau pathology in the brainstem mostly comprised a few neurofibrillary tangles and fell within the range of age-related changes. We found phosphorylated transactivation response element DNA-binding protein 43 kDa (pTDP-43) positive structures in five cases. Four of the five cases were observed in the substantia nigra (SN) but not limbic regions. The distribution pattern of pTDP-43 clearly differed from that in LB disease and older adults, suggesting that nigral degeneration is the primary lesion in the Sagamihara family. TDP-43 pathology in the Sagamihara family was different from those observed in TDP-43 proteinopathy that causes parkinsonism, which could be a secondary change; however, it may influence the course of the disease. Degeneration of the SN with relative preservation of the LC is a consistent finding in Sagamihara families, with or without LBs. These findings suggest that members of the Sagamihara family harbor a synuclein-independent neurodegenerative pathway and exhibit differential vulnerabilities depending on the brain region.

Indexed as

BrainDNA-Binding ProteinsLeucine-Rich Repeat Serine-Threonine Protein Kinase-2MutationParkinson Diseasetau ProteinsAdultAgedFemaleHumansMaleMiddle AgedSubstantia NigraDNA-Binding ProteinsLeucine-Rich Repeat Serine-Threonine Protein Kinase-2LRRK2 protein, humanMAPT protein, humanTARDBP protein, humantau ProteinsLeucine-rich repeat kinase 2Locus coeruleusMultiple system atrophyParkinson's diseaseSubstantia nigraTDP-43

Identifiers

PMID40488901
PMCPMC12148971

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.